Frontlight ResearchEarly access
CompletedPhase 2/3
Effect of Colchicine on the Progression of Aortic Valve Stenosis - A Pilot Study
Key facts
- Who runs it
- Ottawa Heart Institute Research Corporation
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2/3
- People taking part
- 24 people enrolled
- Started
- 1 Jul 2022
- Ended
- 20 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Colchicine 0.6 mg
- Placebo
- Record updated
- 6 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- mild to moderate aortic stenosis defined by a mean pressure gradient using transthoracic echocardiography (TTE) between 15-25mmHg
- age greater than18 years
- given informed consent
Who cannot take part
- Use of p-glycoprotein inhibitor (e.g. cyclosporine, verapamil, or quinidine) or a strong CYP3A4 inhibitor (e.g. ritonavir, clarithromycin, or ketoconazole)
- decompensated heart failure
- active infection (e.g. pneumonia, active skin infections, and on antibiotics)
- immune compromise (e.g. recurrent infection)
- history of cancer within the last 3 years (other than a successfully treated cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix)
- active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate))
- glomerular filtration rate (GFR) <50 ml/min/1.72m2
- Hemoglobin < 105(women) <110 (men) g/L; WBC < 3.0x 10(9)/L, platelet count< 110x 10(9)/L
- Patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease or with alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal
- bicuspid aortic valve
- associated moderate to severe aortic regurgitation
- associated other valvular pathology of moderate or greater severity
- LV dysfunction (EF<50%)
- chronic diarrhea
- pregnancy (all women of child bearing potential will have a negative BHCG test
- breastfeeding
- Women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception
- unable to give informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
COPAS pilot is a pilot single center double blinded randomized study to determine the effect of targeted anti-inflammation therapy using colchicine, on valvular calcification activity using imaging, i.e. aortic valvular NaF uptake. The current proposal uses a randomized design to evaluate the effect of colchicine vs. placebo on valvular calcification activity over 6 months measured using NaF PET
The 2 groups in the trial
- ColchicineTreatment being tested
Colchicine 0.6mg PO daily for 6 months
Treatment: Colchicine 0.6 mg
- PlaceboPlacebo, for comparison
Placebo tablet daily for 6 months
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 6 May 2026